Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Nov
12
Today In Oncology
Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo